Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer

Anticancer Research

Volumn 19, Issue 5 C, 1999, Pages 4469-4474

  Baekelandt, Mark ^a   Kristensen, Gunnar B ^a   Tropé, Claes G ^a   Nesland, Jahn M ^a   Holm, Ruth ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Advanced ovarian cancer; EGFR; Prognosis

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 0033427889     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kristensen GB and Tropé CG: Epithelial ovarian cancer. Lancet 349: 113-117, 1997.
2. Makar AP, Baekelandt M, Tropé CG and Kristensen GB: The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175-180, 1995.
3. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
4. Miyazawa K: Role of epidermal growth factor in obstetrics and gynecology. Obstet Gynecol 79: 1032-1040, 1992.
5. Lipponen P and Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120-1125, 1994.
6. Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL and Min KW: Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 73: 370-376, 1994.
7. Klijn JGM, Berns PMJJ, Schmitz PIM and Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 3-17, 1992.
8. Kristensen GB, Holm R, Abeler VM and Tropé CG: Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor and c-erbB-2 in early cervical squamous cell carcinoma. Cancer 78: 433-440, 1996.
9. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini, Fagotti A and Mancuso S: Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 2: 361-366, 1995.
10. van Dam PA, Vergote IB, Lowe DG, Watson JV, Van Damme P, Van der Auwera JC and Shepherd JH: Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor 1, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 47: 914-919, 1994.
11. van der Burg MEL, Henzen-Logmans SC, Foekens JA, Berns EMJJ, Rodenburg CJ, van Putten WLJ and Klijn JGM: The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer 29A: 1951-1957, 1993.
12. Bauknecht T, Runge M, Schwall M and Pfleiderer A: Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 29: 147-157, 1988.
13. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P and Zeillinger R: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17: 613-620, 1997.
14. Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F and Wagner E: Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 28A: 1432-1437, 1992.
15. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL and Bast RC: Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164: 669-674, 1991.
16. Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C and Scoccia B: Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66: 250-254, 1997.
17. Henzen-Logmans SC, Berns EMJJ, Klijn JGM, van der Burg MEL and Foekens JA: Epidermal growth factor receptor in ovarian tumors: correlation of immunohistochemistry with ligand binding assay. Br J Cancer 66: 1015-1021, 1992.
18. Sorbe B, Trope C, Nordal R, Himmelmann A, Simonsen E, Högberg T, Einhorn N, Pettersson F, Frankendal B, Pettersson B, Tholander B, Svanberg L and Kjörstad K Chemotherapy versus radiotherapy as consolidation treatment of ovarian carcinoma stage III at surgical complete remission from induction chemotherapy. Proceedings ASCO 15: 287, 1996 (abstract).
19. Serov S, Scully R and Sobin L: Histological typing of ovarian tumors. In: World Health Organization: International histological classification of tumors. Geneva, WHO, 1973, vol 9, pp37-42.
20. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
21. Cox DR: Regression models and life tables (with discussion). J R Stat Soc 34: 187-209, 1972.
22. Owens OJ, Stewart C, Leake RE and McNicol AM: A comparison of biochemical and immunohistochemical assessment of EGFR expression in ovarian cancer. Anticancer Res 12: 1455-1458? 1992.
23. Mandai M, Konishi I, Koshiyama M, Mori T, Arao S, Tashiro H, Okamura H, Nomura H, Hiai H and Fukumoto M: Expression of metastasis-related nm23-HI and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex-steroid receptor expression. Cancer Res 54: 1825-1830, 1994.
24. Neal DA, Smith K, Fennelly JA, Bennett MK, Hall RG and Harris AL: Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. J Urol 141: 517-521, 1989.
25. Cohen S: The epidermal growth factor (EGF). Cancer 5: 1787-1791, 1983.
26. Stromberg K, Collins IV TJ, Gordon AW, Jackson CL and Johnson GR: Transforming growth factor-a acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res 52: 341-347, 1992.
27. Morishige K, Kurachi H, Amemiya K, Adachi H, Inoue M, Miyake A, Tanizawa O and Sakoyama: Involvement of transforming growth factor-a/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro. Cancer Res 5: 5951-5955, 1991.
28. Morishige K, Kurachi H, Amemiya K, Fujita Y, Yamamoto T, Miyake A and Tanizawa O: Evidence for the involvement of transforming growth factor-α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 51: 5322-5328, 1991.
29. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH: Synthesis of messenger RNAs for transforming growth factor-α and β and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712, 1987.
30. Perosio PM and Brooks JJ: Expression of growth factors and growth factor receptors in soft tissue tumors. Implications for the autocrine hypothesis. Lab Invest 60: 245-253, 1989.
31. Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelsohn J, Salomon DS and Ciardiello F: Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res 2: 601-609, 1996.
32. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD and Fidler IJ: Level and function of epidermal growth factor receptor predict the μetastatic potential of human colon carcinoma cells. Clin Cancer Res 1: 19-31, 1995.
33. Lichtner RB, Kauf nann AM, Kittmann A, Rohde-Schulz B, Walter J, Williams L Ullrich A, Schirrmacher V and Khazaie K Ligand mediated activation of ectopic mammary adenocarcinoma cells. Oncogene 10: 1823-1832, 1995.
34. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T and Rijksen G: Overexpression of EGFR and c-erbB-2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425: 145-150, 1998.
35. Shiozaki H, Kadowaki T, Doki Y, Inoue M, Tamura S, Oka H, Iwazawa T, Matsui S, Shimaya K, Takeichi M and Mori T: Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 71: 250-258, 1995.
36. Viloria Petit AM, Rak J, Hung M, Rockwell P, Goldstein N, Fendly B and Kerbel R: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am J Pathol 151: 1523-1530, 1997.
37. Mendelsohn J and Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89: 341-343, 1997 (editorial).
38. Dixit M, Yang J, Poirier MC, Price JO, Andrews PA and Arteaga CL: Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 89: 365-373, 1997.
39. Hickmann JA: Apoptosis and chemotherapy resistance. Eur J Cancer 32A: 921-926, 1996.
40. Voldborg BR, Damstrup L, Spang-Thomsen M and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8: 1197-1206, 1997.